ClinicalTrials.gov
public full text
Public Domain
Glutamate Reducing Interventions in Schizophrenia
Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to determine whether these doses of POMA are affecting glutamate levels.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects#1126628
- Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought#1096120
- Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study#980345
- Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia#1243431
- [F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children#1197065
Record · ID 1183906
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive